MTOR and neoplasm: Notably, preclinical and clinical data have suggested efficacy of targeted therapies including MEK or mTOR inhibitors alone or in combination in NF1‐mutated tumors.10, 37, 38 It will be important not only to assess the presence of NF1 mutation in a tumor, but also to accurately assess the potential therapeutic impact of NF1 point mutations, copy number, and the ratio of mutant to normal as predictive biomarkers.39